Riskpilot← Back to searchSign inGet full accessLØRENSKOG ØYEKLINIKK AS
ASActiveOrg 911800357Skårersletta 18, 1473 LørenskogMedical specialists activities · NACE 8622Est. 20138 employees
Revenue 2025
NOK 5,6M
+26% vs 2024
EBITDA margin
0.7%
+10% vs 2024
Equity ratio
26.8%
Financial strength
Net profit 2025
NOK -948
+97% vs 2024
| Revenue | NOK 5,6M | +26% |
| EBITDA | NOK 40K | +10% |
| Net profit | NOK -948 | +97% |
| Total assets | NOK 783K | -5% |
| Equity | NOK 210K | +0% |
| Employees | 8 | — |
Legal name
LØRENSKOG ØYEKLINIKK AS
Org number
911800357
Legal form
Aksjeselskap
NACE code
8622 · Medical specialists activities
Founded
11. april 2013
Share capital
NOK 50 000
Employees
8 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Daglig leder alene. Styrets leder alene.
Company purpose
Spesialiserte legetjenester, øyelegetjenester, helsetjenester, konsultasjoner, utredninger, behandlinger av pasienter med øyesykdommer, undervisning og opplæring av helsepersonell, foredrag, konsulentvirksomhet - samt samarbeid med andre virksomheter samt forretningsvirksomhet som hermed står i forbindelse.
Address
Skårersletta 18, 1473 Lørenskog
Phone
+4763890790
Email
post@legelisten.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 4 350 | 4 270 | 4 070 | 4 470 | 5 630 |
| Staff expenses | −2 271 | −2 261 | −2 247 | −2 680 | −3 526 |
| EBITDA | 86 | 40 | −52 | 36 | 40 |
| Depreciation & amort. | −93 | −84 | −30 | −41 | −41 |
| EBIT | −7 | −44 | −82 | −5 | −1 |
| Net financials | 0 | 0 | 2 | 4 | −0 |
| Profit before tax | −6 | −44 | −80 | −1 | −1 |
| Tax | −5 | 22 | −17 | 35 | −0 |
| Net profit | −1 | −65 | −62 | −36 | −1 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 781 | 781 | 663 | 828 | 783 |
| Equity | 375 | 309 | 247 | 211 | 210 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 406 | 471 | 416 | 617 | 573 |
| Total debt | 406 | 471 | 416 | 617 | 573 |
EBITDA margin
0.7%
This company
15.8%
Market median
-96% vs market
20212025
Equity ratio
26.8%
This company
38.2%
Market median
-30% vs market
20212025
Return on equity
-0.5%
This company
18.4%
Market median
-103% vs market
20212025
Net profit margin
-0.0%
This company
8.1%
Market median
-100% vs market
20212025
Asset turnover
7.19×
This company
1.12×
Market median
+542% vs market
20212025
Debt / equity
2.73×
This company
0.62×
Market median
-340% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AB Chief Executive Officer | Chief Executive Officer | 2013 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2013 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 50% | 50% | 2022 | |
| Company | 50% | 50% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Effekt As
LØRENSKOG ØYEKLINIKK AS Board members of LØRENSKOG ØYEKLINIKK AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Awn Bin Akil Syed | Chief Executive Officer | 0 companies |
| Faranak Asadi | Chairman | 0 companies |